Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn - 08/09/11
Doi : 10.1016/S0022-3476(99)70462-2
Abstract |
Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia. Current treatments of patients with SCFN-related hypercalcemia are often only partially successful and may be associated with prolonged hypercalcemia. We now report the use of etidronate, a bisphosphonate, to control hypercalcemia in an infant with SCFN. (J Pediatr 1999;134:349-51)
Le texte complet de cet article est disponible en PDF.Abbreviations : SCFN
Plan
 | Reprint requests: Alan M. Rice, MD, Yale Pediatrics, Endocrinology, PO Box 208081, 464 Congress Ave, New Haven, CT 06520. |
| 0022-3476/99/$8.00 + 0 9/22/95109 |
© 1999
Mosby, Inc. Tous droits réservés.
Vol 134 - N° 3
P. 349-351 - mars 1999 Retour au numéro
Article précédent
- Latex sensitization in spina bifida appears disease-associated
- Zsolt Szépfalusi, Rainer Seidl, Günther Bernert, Wolfgang Dietrich, Susanne Spitzauer, Radvan Urbanek
- Respiratory chain complex III deficiency with pruritus: A novel vitamin responsive clinical feature
- David Mowat, Denise M. Kirby, K.Ramanand Kamath, Alex Kan, David R. Thorburn, John Christodoulou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?